AP Biosciences Inc
AP Biosciences Inc researches and develops protein and antibody drugs for unmet medical needs. It develops IBI302 that is in phase III clinical trials for the treatment of neovascular age-related macular degeneration; AP505 that is in phase I clinical trials for treating solid tumors; AP203 that is in phase I clinical trial for non-small cell lung cancer, head and neck squamous cell carcinoma, an… Read more
AP Biosciences Inc (6945) - Total Assets
Latest total assets as of September 2025: NT$1.46 Billion TWD
Based on the latest financial reports, AP Biosciences Inc (6945) holds total assets worth NT$1.46 Billion TWD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
AP Biosciences Inc - Total Assets Trend (2020–2024)
This chart illustrates how AP Biosciences Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
AP Biosciences Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
AP Biosciences Inc's total assets of NT$1.46 Billion consist of 91.6% current assets and 8.4% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 83.5% |
| Accounts Receivable | NT$4.89 Million | 0.3% |
| Inventory | NT$0.00 | 0.0% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$3.55 Million | 0.2% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2020–2024)
This chart illustrates how AP Biosciences Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AP Biosciences Inc's current assets represent 91.6% of total assets in 2024, a decrease from 97.0% in 2020.
- Cash Position: Cash and equivalents constituted 83.5% of total assets in 2024, down from 96.7% in 2020.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 884.0% in 2020.
- Asset Diversification: The largest asset category is accounts receivable at 0.3% of total assets.
AP Biosciences Inc Competitors by Total Assets
Key competitors of AP Biosciences Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
AP Biosciences Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - AP Biosciences Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - AP Biosciences Inc is currently not profitable relative to its asset base.
AP Biosciences Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.55 | 24.80 | 242.10 |
| Quick Ratio | 18.55 | 24.80 | 242.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$1.25 Billion | NT$ 734.77 Million | NT$ 1.09 Billion |
AP Biosciences Inc - Advanced Valuation Insights
This section examines the relationship between AP Biosciences Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.52 |
| Latest Market Cap to Assets Ratio | 0.14 |
| Asset Growth Rate (YoY) | 93.9% |
| Total Assets | NT$1.73 Billion |
| Market Capitalization | $241.37 Million USD |
Valuation Analysis
Below Book Valuation: The market values AP Biosciences Inc's assets below their book value (0.14 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: AP Biosciences Inc's assets grew by 93.9% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for AP Biosciences Inc (2020–2024)
The table below shows the annual total assets of AP Biosciences Inc from 2020 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.73 Billion | +93.90% |
| 2023-12-31 | NT$890.76 Million | -19.26% |
| 2022-12-31 | NT$1.10 Billion | +90.42% |
| 2021-12-31 | NT$579.35 Million | +88753.32% |
| 2020-12-31 | NT$652.02K | -- |